Cell Therapy Patents

Cell therapy patents cover chimeric antigen receptor CAR construct design; viral and non-viral CAR transduction methods; T cell manufacturing and process; allogeneic cell engineering for off-the-shelf products; and tumor infiltrating lymphocyte TIL expansion — with IP concentrated in founding academic groups; large pharma; and a set of well-funded biotechs: MAJOR CELL THERAPY PATENT HOLDERS: UNIVERSITY OF PENNSYLVANIA (NOVARTIS LICENSE): 300+; specific CD19 CAR-T construct (specific specific FMC63 scFv CD19-binding domain + specific specific CD8α hinge+transmembrane domain + specific specific 4-1BB costimulatory domain + specific specific CD3ζ signaling domain from specific specific June/Levine group for specific specific CTL019/tisagenlecleucel Kymriah for specific specific B-ALL+DLBCL; specific specific 4-1BB advantage: specific specific 4-1BB vs. specific specific CD28 costimulatory domain for specific specific improved T cell persistence + specific specific memory phenotype + specific specific longer remission duration in specific specific clinical data for specific specific Kymriah regulatory basis); MEMORIAL SLOAN KETTERING / ST. JUDE (BMS LICENSE): 200+; specific CD19 CAR-T (specific specific FMC63 scFv + specific specific CD28 hinge/TM + specific specific 4-1BB + specific specific CD3ζ for specific specific lisocabtagene maraleucel Breyanzi from specific specific two-product CD4:CD8 defined ratio manufacturing for specific specific defined composition vs. specific specific uncontrolled ratio at specific specific 1:1 for specific specific DLBCL + specific specific CLL approved); KITE PHARMA (GILEAD): 500+; specific CD19/CD22 CAR-T (specific specific FMC63 CD19 + specific specific CD28 TM+costimulatory domain for specific specific axi-cel Yescarta from specific specific CD28 vs. specific specific 4-1BB costimulatory for specific specific faster expansion + specific specific peak efficacy at specific specific cost of specific specific shorter persistence; specific specific KRAS G12D T cell receptor TCR engineered for specific specific solid tumor; specific specific 3-4 day manufacturing process for specific specific shortest turnaround CAR-T); NOVARTIS ONCOLOGY: 500+; specific tisagenlecleucel manufacturing+commercial (specific specific closed system automated CliniMACS Prodigy for specific specific leukapheresis+selection+transduction+expansion for specific specific 22-day manufacturing turnaround); JUNO THERAPEUTICS (BMS): 400+; specific CD28 and 4-1BB CAR-T variants; ABBVIE; JANSSEN; BLUEBIRD BIO; FATE THERAPEUTICS: 200+ each.

Allogeneic off-the-shelf cell therapy from donor-derived or iPSC-derived sources; natural killer NK cell therapy engineering; and non-viral CAR transduction using mRNA, transposons, or electroporation represent three actively developing cell therapy innovation areas with significant IP whitespace vs. autologous CAR-T: ALLOGENEIC CELL THERAPY PATENTS: ALLOGENE THERAPEUTICS (PFIZER); CELYAD ONCOLOGY; PRECISION BIOSCIENCES; INTELLIA THERAPEUTICS; EDITAS MEDICINE; CELLECTIS; CARIBOU BIOSCIENCES: specific allogeneic cell therapy (specific specific CRISPR TRAC knock-in: specific specific CRISPR-Cas9 guide RNA targeting specific specific TRAC T cell receptor alpha constant locus for specific specific TCR disruption + specific specific HDR homology directed repair CAR knock-in at specific specific TRAC locus for specific specific simultaneous TCR removal to prevent GvHD + specific specific CAR integration for specific specific allogeneic CAR-T from specific specific healthy donor T cell; specific specific B2M CIITA dual knockout: specific specific CRISPR B2M + specific specific CIITA knockouts for specific specific HLA class I + specific specific class II elimination for specific specific reduced host immune rejection of specific specific allogeneic cell for specific specific universal donor compatibility; specific specific TALEN TRAC knockout: specific specific Cellectis TALEN heterodimer for specific specific TRAC+TRBC TCR alpha+beta knockout for specific specific allogeneic T cell for specific specific UCART19 product); NK CELL THERAPY PATENTS: FATE THERAPEUTICS; NKARTA; NKGEN BIOTECH; CYTOVIA THERAPEUTICS; MEMORIAL SLOAN KETTERING: specific NK cell (specific specific iPSC-derived NK cell: specific specific Fate Therapeutics from specific specific H9 iPSC hematopoietic differentiation for specific specific clonally derived NK cell with specific specific engineered CD16 158V/V high-affinity Fc receptor + specific specific IL-15/IL-15Rα fusion transgene for specific specific persistence without specific specific cytokine support for specific specific FT516 off-the-shelf NK product; specific specific CAR-NK: specific specific CD19 CAR + specific specific retroviral transduction in specific specific NK-92 cell line for specific specific CAR-NK off-the-shelf at specific specific faster manufacturing vs. specific specific autologous CAR-T without specific specific GvHD risk); NON-VIRAL CAR DELIVERY PATENTS: POSEIDA THERAPEUTICS; INTIMA BIOSCIENCE; UMOJA BIOPHARMA; NCARDIA: specific non-viral CAR delivery (specific specific piggyBac transposon: specific specific Poseida Therapeutics PiggyBac transposase+transposon system for specific specific non-viral genomic CAR integration from specific specific electroporation of specific specific hyperactive PB transposase mRNA + specific specific CAR transposon for specific specific multi-copy integration for specific specific higher expression + specific specific no lentiviral vector cost; specific specific sleeping beauty transposon: specific specific SB100X transposase for specific specific non-viral T cell engineering with specific specific regulatory accepted synthetic DNA vector for specific specific reduced immunogenicity vs. specific specific viral vector at specific specific lower manufacturing cost).

Tumor infiltrating lymphocyte TIL therapy using ex vivo expanded autologous TIL; T cell receptor TCR-engineered T cell therapy targeting intracellular neoantigens; and regulatory T cell Treg therapy for autoimmune disease and transplant tolerance represent three additional cell therapy domains with distinct patent landscapes: TIL THERAPY PATENTS: IOVANCE BIOTHERAPEUTICS (FORMERLY TIL BIOTHERAPEUTICS); NCI ROSENBERG GROUP; ADAPTIMMUNE: specific TIL therapy (specific specific REP rapid expansion protocol: specific specific TIL REP from specific specific Rosenberg NCI for specific specific anti-CD3 OKT3 + specific specific IL-2 1000 IU/mL + specific specific irradiated feeder cell from specific specific peripheral blood mononuclear cell PBMC at specific specific 200:1 feeder:TIL ratio for specific specific 1000× expansion in specific specific 11-14 day for specific specific infusion-ready TIL from specific specific tumor resection biopsy; specific specific Gen-2 TIL process: specific specific Iovance 16-22 day Gen-2 shortened protocol from specific specific pre-REP+REP for specific specific centralized manufacturing for specific specific lifileucel FDA approval Feb 2024 unresectable melanoma; specific specific Neoantigen TIL: specific specific tumor biopsy WES whole-exome sequencing → specific specific neoantigen prediction → specific specific TIL neoantigen-reactive clone enrichment for specific specific highly reactive TIL); TCR-ENGINEERED T CELL PATENTS: ADAPTIMMUNE; IMMUNOCORE; GRITSTONE BIO; MEDIGENE; KITE PHARMA/GILEAD: specific TCR-T (specific specific MAGE-A4 TCR: specific specific Adaptimmune SPEAR T cell from specific specific affinity-enhanced TCR for specific specific HLA-A*02:01 MAGE-A4 intracellular antigen for specific specific synovial sarcoma FDA-approved afami-cel 2024; specific specific CD8 coreceptor bypass: specific specific TCR construct with specific specific co-expressed CD8α/β for specific specific class I MHC restricted TCR function in specific specific CD4+ T cell for specific specific broader CD4 response; specific specific pHLA half-life: specific specific Immunocore ImmTAC bispecific from specific specific affinity-enhanced TCR fused to specific specific anti-CD3 effector function for specific specific redirected T cell killing without specific specific T cell engineering); TREG THERAPY PATENTS: SANGAMO THERAPEUTICS; QUELL THERAPEUTICS; TXINNO; REGULATORY T CELL INC: specific Treg therapy (specific specific polyclonal Treg expansion: specific specific CD4+CD25+FoxP3+ Treg from specific specific peripheral blood for specific specific GMP expansion with specific specific rapamycin selection for specific specific transplant tolerance clinical trial; specific specific CAR-Treg: specific specific HLA-A2 CAR Treg from specific specific Sangamo TX200 for specific specific kidney transplant tolerance donor-specific suppression at specific specific organ with specific specific limited off-target Treg activity for specific specific safer profile vs. specific specific polyclonal Treg).

Cell therapy startup IP strategy must navigate one of the most IP-dense and contested biopharmaceutical patent landscapes — with autologous CAR-T largely controlled by Penn/Novartis and MSK/BMS; significant freedom to operate in allogeneic, NK, non-viral, and TIL spaces; and the unique challenge of process patent importance in cell therapy manufacturing: CELL THERAPY STARTUP IP STRATEGY: UNDERSTAND THE CELL THERAPY PATENT LANDSCAPE: AUTOLOGOUS CAR-T = CROWDED IP LANDSCAPE: Penn/Novartis CD19 4-1BB CD3ζ (Kymriah) + MSK/BMS CD19 defined ratio (Breyanzi) + Kite/Gilead CD19 CD28 (Yescarta) = the core autologous CAR-T landscape; new entrants targeting CD19 B-ALL/DLBCL face overlapping foundational patents from all three; ALLOGENEIC = ACTIVE WHITESPACE: Cellectis (TALEN), Intellia/Caribou (CRISPR-Cas9), Precision Biosciences (ARC nuclease), and Allogene (split-intein) hold distinct allogeneic engineering IP — less concentrated than autologous, more IP room for novel approaches; FATE THERAPEUTICS iPSC-DERIVED IP: Fate Therapeutics (200+) holds key iPSC-derived NK and T cell manufacturing IP — important FTO item for any iPSC cell therapy program; IOVANCE TIL FDA APPROVAL = VALIDATED PATENT MOAT: Iovance's lifileucel received FDA approval 2024 with REP manufacturing process patents; TIL process patents are process-based and cover specific expansion conditions; TCR-T SPACE: Adaptimmune + Immunocore hold foundational affinity-enhanced TCR IP; GSK acquired Adaptimmune pipeline 2024; WHEN TO PATENT IN CELL THERAPY: NOVEL CAR CONSTRUCT WITH MEASURED FUNCTIONAL OUTCOME: specific novel CAR architecture (specific specific scFv or specific specific nanobody + specific specific hinge+TM + specific specific costimulatory combination + specific specific signaling domain) with specific measured in vitro function (specific specific target-specific killing EC50 nM + specific specific cytokine secretion IL-2+IFN-γ pg/mL + specific specific CAR T cell expansion fold over specific specific days) + specific specific in vivo animal efficacy (specific specific tumor volume reduction % + specific specific survival improvement days vs. specific specific control) vs. specific specific CD19 4-1BB CD3ζ baseline — include specific functional data across specific specific antigen density range; NOVEL ALLOGENEIC ENGINEERING METHOD: specific novel genome editing approach (specific specific guide RNA sequence + specific specific nuclease + specific specific delivery method) with specific measured knockout efficiency % at specific specific target locus + specific specific on-target insertion % + specific specific off-target indel rate at specific specific predicted off-target sites + specific specific T cell viability % post-editing + specific specific GvHD-prevention in specific specific in vivo xenograft assay vs. specific specific prior art allogeneic engineering method; NOVEL MANUFACTURING PROCESS: specific novel manufacturing step (specific specific selection protocol or specific specific expansion medium + specific specific cytokine combination or specific specific gene transduction condition) with specific measured cell product attribute (specific specific CD4:CD8 ratio + specific specific central memory % + specific specific transduction efficiency % + specific specific potency assay value at specific specific final product) vs. specific specific conventional manufacturing protocol — process patents are undervalued but powerful moats in cell therapy; § 101: cell therapy = biological method + composition of cells + CAR DNA construct = clearly patent-eligible; no meaningful § 101 risk for cell therapy hardware/composition; TRADE SECRETS: specific manufacturing medium formula; specific cytokine cocktail; leukapheresis quality spec; CAR vector map beyond disclosure requirements; KEY FTO: Penn/Novartis FMC63 CD19 scFv + 4-1BB + CD3ζ construct Kymriah; MSK/BMS CD4:CD8 defined ratio lisocabtagene manufacturing; Kite/Gilead CD28 TM+costimulatory Yescarta; Cellectis TALEN TRAC+TRBC allogeneic; Fate Therapeutics iPSC-NK CD16 158V/V + IL-15 fusion; Iovance REP OKT3 IL-2 1000 IU/mL irradiated feeder 200:1; Adaptimmune affinity-enhanced TCR MAGE-A4 HLA-A*02:01; Poseida PiggyBac hyperactive transposase non-viral.